CD4 and neoplasm: These results indicate that treatment with TH-Trastuzumab-MCC-CpG conjugate is superior in inducing antigen-specific CD4 T cells in comparison to a combination of unconjugated Trastuzumab and CpG, even though both treatment groups are similarly effective in reducing tumor burden.